Source link : https://www.newshealth.biz/health-news/viridian-shares-soar-after-latest-trial-success-for-thyroid-eye-disease-drug/
(Reuters) -Viridian Therapeutics’ experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares surging more than 26%. The success of the antibody drug, veligrotug, follows a separate late-stage study in September where it helped reduce symptoms in patients with active […]
Author : News Health
Publish date : 2024-12-16 12:10:07
Copyright for syndicated content belongs to the linked Source.